Publication Date: 15 Oct 2012
Type: Case report
Journal: Clinical Medicine Insights: Case Reports
doi: 10.4137/CCRep.S8825
Intravenous zoledronic acid (ZOL) is an integral component for the management of patients with bone metastases, but can be associated with transient flu-like symptoms, which generally occur only with the first infusion and are typically manageable with nonprescription analgesics. A 50-year-old woman with a bone metastasis secondary to breast cancer received radiation therapy, brand-name ZOL (Zometa®), and letrozole. During the first 3 cycles of Zometa (4 mg every 3–4 weeks), no acute adverse events were reported. For the next 2 cycles she was switched to generic ZOL and experienced severe toxicity (nausea, vomiting, extreme weakness, and incapacitating bone pain) that required hospitalization. Toxicity differences between generic ZOL and Zometa led the patient to pay additional costs for Zometa, and subsequent Zometa infusions were without incident. This is the first case report documenting a clinically significant difference between the safety profiles of a generic formulation of ZOL and brand-name Zometa.
PDF (367.08 KB PDF FORMAT)
RIS citation (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)
BibTex citation (BIBDESK, LATEX)
PMC HTML
My experience with Clinical Medicine Insights: Case Reports was excellent. The entire review process was fast and accurate. My previous experience with important top ranking journals was unpleasant mainly because the staff were slow and sometimes presumptuous. On the contrary, the editors of Libertas were helpful and prompt in responding to questions and issues related to the submission. I recommend the publisher to my colleagues.
All authors are surveyed after their articles are published. Authors are asked to rate their experience in a variety of areas, and their responses help us to monitor our performance. Presented here are their responses in some key areas. No 'poor' or 'very poor' responses were received; these are represented in the 'other' category.See Our Results
Copyright © 2013 Libertas Academica Ltd (except open access articles and accompanying metadata and supplementary files.)
FacebookGoogle+Twitter
PinterestTumblrYouTube